APRE Stock Summary and Trading Ideas (Aprea Therapeutics | NASDAQ:APRE)

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.

As of July 9, 2026, APRE stock price declined to $0.73 with 39,082 million shares trading.

APRE has a beta of 3.08, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.26 to the broad based SPY ETF.

APRE has a market cap of $9.01 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APRE traded as high as $8.85 and as low as $.55.

The top ETF exchange traded funds that APRE belongs to (by Net Assets): VXF.

APRE has underperformed the market in the last year with a price return of -59.6% while the SPY ETF gained +22.4%. APRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.8% and -9.9%, respectively, while the SPY returned +11.5% and +2.5%, respectively.

APRE support price is $.70 and resistance is $.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE shares will trade within this expected range on the day.